Shares of Intersect ENT, Inc. (NASDAQ:XENT) have been given a consensus rating of “Buy” by the fourteen research firms that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $27.70.
A number of equities analysts have recently commented on the stock. TheStreet raised shares of Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Wednesday, July 26th. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price target on shares of Intersect ENT and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $32.00 price target on shares of Intersect ENT in a research report on Wednesday, August 2nd.
COPYRIGHT VIOLATION WARNING: “Intersect ENT, Inc. (XENT) Receives Average Rating of “Buy” from Analysts” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/01/intersect-ent-inc-xent-receives-average-rating-of-buy-from-analysts.html.
In other Intersect ENT news, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $30.79, for a total value of $615,800.00. Following the sale, the insider now owns 525,868 shares of the company’s stock, valued at approximately $16,191,475.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $29.00, for a total transaction of $372,157.00. Following the completion of the sale, the chief financial officer now directly owns 27,833 shares in the company, valued at approximately $807,157. The disclosure for this sale can be found here. Insiders sold a total of 134,563 shares of company stock worth $4,014,904 in the last three months. Insiders own 13.70% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Legal & General Group Plc increased its holdings in Intersect ENT by 3.8% in the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the period. Moors & Cabot Inc. bought a new stake in Intersect ENT in the 2nd quarter valued at $205,000. Prudential Financial Inc. bought a new stake in Intersect ENT in the 2nd quarter valued at $229,000. Cubist Systematic Strategies LLC bought a new stake in Intersect ENT in the 2nd quarter valued at $229,000. Finally, HighTower Advisors LLC bought a new stake in Intersect ENT in the 2nd quarter valued at $231,000. 83.08% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Intersect ENT (XENT) opened at 29.65 on Wednesday. The firm’s market capitalization is $865.45 million. Intersect ENT has a 12-month low of $7.65 and a 12-month high of $33.25. The company’s 50-day moving average is $29.65 and its 200-day moving average is $27.29.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The company had revenue of $24.00 million for the quarter, compared to analyst estimates of $22.62 million. During the same quarter last year, the firm posted ($0.21) earnings per share. The company’s quarterly revenue was up 24.4% compared to the same quarter last year. On average, equities analysts forecast that Intersect ENT will post ($0.61) earnings per share for the current fiscal year.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
What are top analysts saying about Intersect ENT Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intersect ENT Inc. and related companies.